Dulac Edward J III sold $84K of NTLA
Dulac Edward J III (EVP, Chief Financial Officer) sold 4,677 shares of Intellia Therapeutics, Inc. (NTLA) at $18.00 on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
For trading, the key takeaway is disclosure of insider liquidity/diversification rather than a new operational or financial development.
Market read
Discloses a specific insider sale (4,677 shares at $18.00) with post-transaction holdings of 156,286 shares.
What to watch
The sale size ($84K) is modest relative to typical institutional flows; without additional context (e.g., multiple concurrent insider sales), the signal is weak.
Background
The filing is an SEC Form 4 insider transaction by the company’s CFO, executed under a pre-arranged Rule 10b5-1 plan.
Ticker impact
Intellia Therapeutics CFO Dulac Edward J III sold 4,677 shares on a 10b5-1 plan for about $84.2K at $18.00/share.
Likely minimal near-term impact; any effect would be sentiment-only and typically short-lived.
Form 4 insider sales can be interpreted as diversification, and the filing explicitly states a pre-arranged 10b5-1 plan, reducing signal strength versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction data.
None.
None.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with internal expectations of near-term risk, so traders may watch for follow-on disclosures.
Key entities
- issuerIntellia Therapeutics, Inc.
Subject of the Form 4 insider sale by its CFO.
- insiderDulac Edward J III
EVP and Chief Financial Officer who sold shares under a 10b5-1 plan.
